The preliminary therapeutic proof, as well as the probable pharmacological advantages of 5‐MeO‐copyright as opposed to other classical psychedelics, has confirmed intriguing to researchers and pharmaceutical firms alike, fueling a escalating variety of scientific trials which can be at the moment in different phases of growth (Desk 1). At pres